The in vitro evaluation of polyethylene glycol esters of hydrocortisone 21-succinate as ocular prodrugs

International Journal of Pharmaceutics

Volumn 182, Issue 1, 1999, Pages 79-92

  Foroutan, S M ^a   Watson, D G ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Corneal and scleral penetration; Corneal enzymes; Hydrocortisone; Polyethylene glycol esters; Prodrug; Surface activity

Indexed keywords

ESTERASE; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; MACROGOL DERIVATIVE; PRODRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG HYDROLYSIS; DRUG PENETRATION; IN VITRO STUDY; LIPOPHILICITY; MICELLE; NONHUMAN; PRIORITY JOURNAL; SCLERA; SHEEP; SURFACE TENSION; TISSUE HOMOGENATE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; ESTERASES; ESTERS; HYDROCORTISONE; LIVER; OPHTHALMIC SOLUTIONS; POLYETHYLENE GLYCOLS; PRODRUGS; SCLERA; SHEEP; SURFACE TENSION; SWINE;

EID: 0032922572     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00059-9     Document Type: Article

References (46)

1. Ahmed I., Patton T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26:1985;584-587.
2. Ahmed I., Gokhale R.D., Shah M.V., Patton T.F. Physicochemical determinants of drug diffusion across the conjunctiva, sclera and cornea. J. Pharm. Sci. 76:1987;583-586.
3. Anderson B.D., Conradi R.A. Application of physical organic concepts in vivo lability design of water soluble prodrugs. Roche E.B. Bioreversible Carriers in Drug Design. 1987;121-161 Pergamon Press, New York.
4. Attwood D., Florence A.T. Surfactant Systems. 1983;1-39 Chapman and Hall, London.
5. Attwood D., Florence A.T. Surfactant Systems. 1983;124-228 Chapman and Hall, London.
6. Bailon P., Fung W.J., Porter J.E. Strategies for the preparation and characterisation of polyethylene glycol (PEG) conjugated pharmaceutical proteins. Abstr. Papers Am. Chem. Soc. 213(Pt 2):1997;183. -POLY.
7. Bentley M.D., Chung B.Y. PEG-linked artemesinin antimalarials. Abstr. Papers Am. Chem. Soc. 213(Pt 2):1997;217. -POLY.
8. Bonina F.P., Montenegro L., Caprariis D., Palagiano F., Trapani G., Liso G. In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs. J. Control. Release. 34:1995;223-232.
9. Bonina F.P., Montenegro L., Caprariis P.D., Palagiano F., Capasso A., Sorrentino L. Pharmacokinetic and pharmacodynamic profiles of triethylene glycol indomethacin ester as a new oral prodrug. J. Control. Release. 41:1996;187-193.
10. Camber O. An in vitro model for determination of drug permeability through the cornea. Acta Pharm. Suec. 22:1985;335-342.
11. Carini R., Poli G., Dianazi M.U., Maddix S.P., Slater T.F., Cheeseman K.H. Comparative evaluation of the antioxidant activity of α-tocopherol, α-tocopherol polyethylene glycol 1000 succinate and α-tocopherol succinate in isolated hepatocytes and liver microsomal suspensions. Biochem. Pharmacol. 39:1990;1597-1601.
12. Cecchi R., Rusconi L., Tanzi M.C., Danusso F. Synthesis and pharmacological evaluation of poly(oxyethylene) derivatives of 4-isobutylphenyl-2-propionic acid (Ibuprofen). J. Med. Chem. 24:1981;622-625.
13. Chang S.C., Lee V.H.L. Influence of chain length on the in vitro hydrolysis of model ester prodrugs by ocular esterases. Curr. Eye Res. 2:1983;651-656.
14. Chien D.S., Homsy J.J., Gluchowski C., Tangliu D.D.S. Corneal and conjunctival scleral penetration of para-aminoclonidine, AGN-190342, and clonidine in rabbit eyes. Curr. Eye Res. 9:1990;1051-1059.
15. Dixon M., Webb E.C. Enzymes. 3rd ed. 1979;Longman, London.
16. Doane M.G., Jensen A.D., Dohlman G.H. Penetration routes of topically applied eye medications. Am. J. Ophthalmol. 85:1978;383-386.
17. Edelhauser H.F., Maren T.H. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch. Ophthalmol. 106:1988;1110-1113.
18. Fenton B., Lauziere K., Welch J., Crowley R., Licari P., Ruebsamen K., Turner B. Manufacturing, characterisation, and pharmacokinetics of a monodisperse PEG-hirudin. Abstr. Papers Am. Chem. Soc. 213(Pt 2):1997;186. -POLY.
19. Foroutan S.M., Watson D.G. Synthesis and characterisation of polyethylene glycol conjugates of hydrocortisone as potential prodrugs for ocular steroid delivery. Int. J. Pharm. 157:1997;103-111.
20. Forrester J.V., Dick A.D., McMenamin P., Lee V.R. Biochemistry. The Eye Basic Sciences in Practice. 1996;137-198 W.B. Saunders, London.
21. Hämäläinen K.M., Kananen K., Auriola S., Kontturi K., Urtti A. Characterisation of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Inves. Ophthalmol. Vis. Sci. 38:1997;627-634.
22. Hitoshi S., Bundgaard H., Lee V.H.L. Design of prodrugs to selectively reduce timolol absorption on the basis of the differential lipophilic characteristics of the cornea and the conjunctiva. Invest. Ophthalmol. Vis. Sci. Suppl. 30:1989;25.
23. Järvinen T., Järvinen K. Prodrugs for improved ocular drug delivery. Adv. Drug Deliv. Rev. 19:1996;203-224.
24. Kawaguchi T., Youssef A.F., Aboul-Fadl T., Omar F.A., Farag H.H., Hasegawa T. Steric parameters in PLE catalysed hydrolysis of N-substituted cytarabine ester prodrugs. Pharmazie. 51:1996;717-719.
25. Kohn J., Gean K.F., Nathan A., Poiani G.J., Riley D.J., Zalipsky S. New drug conjugates - attachment of small molecules to poly(PEG-lys). Abstr. Papers Am. Chem. Soc. 206:1993;258. -pmse.
26. Lee V.H.L., Li V.H.K. Prodrugs for improved ocular drug delivery. Adv. Drug Deliv. Rev. 3:1989;1-38.
27. Li C., Yu D., Inoue T., Yang D.J., Milas L., Hunter N.R., Kim E.E., Wallace S. Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anti-Cancer Drugs. 7:1996;642-648.
28. Liaw J., Robinson J.R. The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers. Int. J. Pharm. 88:1992;125-140.
29. Maurice R.C., Riley M.V. Ocular Pharmokinetics. Graymore C.N. Biochemistry of the Eye. 1970;6-16 Academic Press, London.
30. McGhee C.N.J., Watson D.G., Noble M., Dutton G.N., Healey T., Midgley J.M. Penetration of topically applied prednisolone phosphate into human aqueous humour. Eye. 3:1989;463-467.
31. Nakaoka R., Tabata Y., Yamaoka T., Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J. Control. Release. 46:1997;253-261.
32. Nathan A., Zalipsky S., Kohn J. Strategies for covalent attachment of doxorubicin to poly(PEG-lys), a new water-soluble poly(ether urethane). J. Bioact. Compat. Polym. 9:1994;239-251.
33. Nucci M.L., Shorr R., Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug Deliv. Rev. 6:1991;133-151.
34. Ouchi T., Kuroda H., Ohya Y. Design of antitumor agent terminated poly(ethylene glycol) conjugate as macromolecular prodrug. Abstr. Papers Am. Chem. Soc. 213(Pt 2):1997;216. -POLY.
35. Pang S.N.J. Final report on the safety assessment of polyethylene glycols (PEGs) -6, -8, -32, -75, -150, -14M, -20M. J. Am. Coll. Toxicol. 12:1993;429-457.
36. Pang S.N.J. Final report on the safety assessment of PEG-30, -33, -35, -36, and -40 castor oil and PEG-30 and -40 hydrogenated castor oil. Int. J. Toxicol. 16:1997.
37. Saettone M.F., Chetoni P., Cerbai R., Mazzanti G., Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β blockers, and in vitro/in vivo toxic activity. Int. J. Pharm. 142:1996;103-113.
38. Saifer M.G.P., Williams L.D., Sherman M.R., French J.A., Kwak L.W., Oppenheim J.J. Improved conjugation of cytokines using high molecular weight poly(ethylene)glycol: PEG-GM-CSF as a prototype. Abstr. Papers Am. Chem. Soc. 213(Pt 2):1997;213. -POLY.
39. Schoenwald R.D., Huang H.S Corneal penetration behavior of β-blocking agents I: Physicochemical factors. J. Pharm. Sci. 72:1983;1266-1272.
40. Schottler C., Krish K. Hydrolysis of steroid hormone esters by an unspecific carboxylesterase from pig liver microsomes. Biochem. Pharmacol. 23:1974;2867-2875.
41. Ulbrich K., Strohalm J., Kopecek J. Poly(ethylene glycol)s containing enzymatically degradable bonds. Makromol. Chem. 187:1986;1131-1144.
42. Vincentelli J., Vire J.C., Paul C., Looze Y. Poly(ethylene glycol) derivatized prodrugs through mixed disulfide bond formation: preliminary report on captopril. Int. J. Pharm. 134:1996;147-155.
43. Waltman S.R., Hart W.M. Jr. The cornea. Moses R.A., Hart W.M. Jr. Adler's Physiology of the Eye, Clinical Application. 8th ed. 1987;36-59 C.V. Mosby, St. Louis, MO.
44. Weast R.C. Handbook of Chemistry and Physics. 1975;CRC Press, Ohio.
45. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83:1994;601-606.
46. Zhao X., Harris J.M. Novel degredable PEG esters for drug delivery: synthesis and characterisation. Abstr. Papers Am. Chem. Soc. 213(Pt 2):1997;24. -POLY.